Title:
USE OF LINAGLIPTIN IN CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY
Document Type and Number:
Japanese Patent JP2021095409
Kind Code:
A
Abstract:
To provide efficacious, safe and tolerable antidiabetic therapies.SOLUTION: The present invention relates to DPP-4 inhibitor linagliptin for use in cardio- and/or renoprotective therapy, in diabetic or non-diabetic patients at high vascular risk.SELECTED DRAWING: None
More Like This:
Inventors:
ODD-ERIK JOHANSEN
MAXIMILIAN VON EYNATTEN
THOMAS KLEIN
HANS-JUERGEN WOERLE
MAXIMILIAN VON EYNATTEN
THOMAS KLEIN
HANS-JUERGEN WOERLE
Application Number:
JP2021030485A
Publication Date:
June 24, 2021
Filing Date:
February 26, 2021
Export Citation:
Assignee:
BOEHRINGER INGELHEIM INT
International Classes:
C07D487/04; A61K31/155; A61K31/198; A61K31/4184; A61K31/4439; A61K31/451; A61K31/522; A61K31/64; A61K38/28; A61K45/00; A61P3/10; A61P9/00; A61P9/04; A61P9/10; A61P9/14; A61P13/12; A61P25/28; A61P43/00
Foreign References:
| WO2012065993A1 | 2012-05-24 |
Attorney, Agent or Firm:
Shinichiro Tanaka
Hiroyuki Suda
Kazuo Yamazaki
Satsuki Ichikawa
Hironobu Hattori
Gen Tashiro
Hiroyuki Suda
Kazuo Yamazaki
Satsuki Ichikawa
Hironobu Hattori
Gen Tashiro